Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands.

ABSTRACT:

Introduction

The progression-free survival of patients with HER2-positive metastatic breast cancer is significantly extended by a combination of two monoclonal antibodies, trastuzumab and pertuzumab, which target independent epitopes of the extracellular domain of HER2. The improved efficacy of the combination over individual antibody therapies targeting HER2 is still being investigated, and several molecular mechanisms may be in play: the combination downregulates HER2, improves antibody-dependent cell mediated cytotoxicity, and/or affects the organization of surface-expressed antigens, which may attenuate downstream signaling.

Methods

By combining protein engineering and quantitative single molecule localization microscopy (qSMLM), here we both assessed and optimized clust

SUBMITTER: Wakefield DL 

PROVIDER: S-EPMC10149953 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature